MEK1/2 inhibitors in the treatment of gynecologic malignancies.

Miller, Caela R; Oliver, Kate E; Farley, John H

Miller, Caela R; Oliver, Kate E; Farley, John H.

Afiliação

Miller CR; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, San Antonio Military Medical Center, 3551 Roger Brooke Road, Ft. Sam, Houston, TX 78234, USA.
Oliver KE; Division of Gynecologic Oncology, Gynecologic Cancer Center of Excellence, Walter Reed National Military Medical Center, 8901 Wisconsin Avenue, Bethesda, MD 20814, USA.
Farley JH; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Arizona Cancer Center, Creighton University School of Medicine at St. Joseph's Hospital and Medical Center, a Dignity Health Member, 500 W. Thomas Road, Suite 600, Phoenix, AZ 85013, USA. Electronic address: John.farley@chw.edu.

Gynecol Oncol ; 133(1): 128-37, 2014 Apr.

Article em En | MEDLINE | ID: mdl-24434059

Assuntos

Carcinoma/tratamento farmacológico; MAP Quinase Quinase 1/antagonistas & inibidores; MAP Quinase Quinase 2/antagonistas & inibidores; Neoplasias Ovarianas/tratamento farmacológico; Inibidores de Proteínas Quinases/uso terapêutico; Carcinoma/enzimologia; Neoplasias Colorretais/tratamento farmacológico; Feminino; Humanos; MAP Quinase Quinase 1/fisiologia; MAP Quinase Quinase 2/fisiologia; Sistema de Sinalização das MAP Quinases/fisiologia; Neoplasias Ovarianas/enzimologia

Palavras-chave

Cancer; Low grade; MAPK cascade; MEK inhibitors; Ovarian; Serous

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Carcinoma / MAP Quinase Quinase 1 / MAP Quinase Quinase 2 / Inibidores de Proteínas Quinases Idioma: En Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google